Reuters: Merck withholds forecasts after cholesterol study

[chris]

Merck withholds forecasts after cholesterol study
      

NEW YORK (Reuters) - Merck & Co Inc cut its sales outlook on two key medicines on Monday and indicated its financial forecasts were in doubt after a mostly negative study of cholesterol treatment Vytorin, sending its shares down 7 percent.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login